A small retrospective study (RT Khalaf et al.NCP 2018; LINK: doi.org/10.1002/ncp.10219) showed that PEG placement was associated with a trend (not statistically significant) towards improved lung function in children with cystic fibrosis (CF). Reference from Kipp Ellsworth twitter feed. There were 20 patients who had PEG placed compared to 40 patients who did not.
- BMI percentile increased per month for those with PEG (0.51, 95% confidence interval (CI) = −0.05–1.08, P = .08), but decreased for those without PEG (−0.03, 95% CI = −0.33–0.28, P = .86); however, the difference (0.54; 95% CI = −0.10–1.18, P = .10) was not statistically significant.
- FEV1 change with time showed a decrease for patients with PEG (−0.04; 95% CI = −0.30–0.22, P = .74) and those without PEG (−.22; 95% CI = −0.45–0.01, P = .06). Although the FEV1 decrease for those without PEG was higher than those with PEG, the difference between the groups was not statistically significant (0.18; 95% CI = −0.17–0.52, P = .32)
My take: While the differences are not statistically-significant, this study indicates that PEG placement is NOT detrimental to lung function in CF and may be beneficial.
Related blog posts:
- Why Do Canadians with Cystic Fibrosis Live Longer?
- Gastrostomy Tubes for Children with Cystic Fibrosis
- Lumacaftor-Ivacaftor for Cystic Fibrosis
- Ivacaftor for Cystic Fibrosis | gutsandgrowth
- CFTR Modulators for Cystic Fibrosis
- FDA Expands Use of Cystic Fibrosis Medication | gutsandgrowth
- “Origins of Cystic Fibrosis Lung Disease”